secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001787306-26-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M
----------------------------------------------------------------------

- Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.
- Net loss of $11.3M ($0.09 per share) vs $25.1M loss in Q1 2025; positive operating cash flow of $2.2M.
- FY 2026 revenue guidance maintained at $480M–$495M; cash and equivalents $224.3M at quarter end.
- Submitted sNDA for ZORYVE cream 0.05% in atopic dermatitis for infants 3–24 months; initiated Phase 1 for ARQ-234.
- Completed dermatology sales force expansion; hired head of Primary Care Franchise to target pediatric providers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/0001787306-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/arqt-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001787306-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer